학술논문
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin typesCapsule Summary
Document Type
article
Author
Angela L. Bosma, MD; Wouter Ouwerkerk, PhD; Madeline J. Heidema, MD; David Prieto-Merino, PhD; Michael R. Ardern-Jones, MD, PhD; Paula Beattie, MD; Sara J. Brown, MD, PhD; John R. Ingram, MD, PhD; Alan D. Irvine, MD, DSc; Graham Ogg, MD, PhD; Prakash Patel, BSc; Nick J. Reynolds, MD, PhD; R.M. Ross Hearn, MD; Mandy Wan, PhD; Richard B. Warren, MD, PhD; Richard T. Woolf, MD, PhD; Ariënna M. Hyseni; Louise A.A. Gerbens, MD, PhD; Phyllis I. Spuls, MD, PhD; Carsten Flohr, MD, PhD; Maritza A. Middelkamp-Hup, MD, PhD
Source
JAAD International, Vol 10, Iss , Pp 14-24 (2023)
Subject
Language
English
ISSN
2666-3287
Abstract
Background: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types. Objective: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type. Methods: In an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL (treatregister.nl) and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; astar-register.org) registries, data on morphological phenotypes and treatment outcomes were investigated. Results: A total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, n = 156 [Ethnicity, White: 94.2%]; dark skin types [DST]: skin type 4-6, n = 68 [Black African/Afro-Caribbean: 25%, South-Asian: 26.5%, and Hispanics: 0%]). DST were younger (19.5 vs 29.0 years; P .05). Limitations: Unblinded, non-randomized. Conclusion: Atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.